Abintus is developing off-the-shelf genetic medicines that utilize in vivo cell engineering through a clinically proven Modular Delivery Platform to directly modify patients' immune cells for targeted therapies. These treatments aim to enhance the immune response against various diseases, including leukemia and solid tumors, by enabling precise gene expression and simultaneous engineering of diverse immune cell types.

Actuate Therapeutics develops elraglusib, a GSK-3 inhibitor that targets multiple molecular pathways to slow, stop, or shrink tumors in patients with hard-to-treat cancers. This approach aims to enhance anti-tumor immunity while minimizing adverse effects associated with conventional therapies.

This platform streamlines patient discharge from hospitals to post-acute care (PAC) facilities, reducing the length of stay. The HIPAA-compliant software expedites the discharge process, ensuring secure and efficient transitions for patients requiring continued care.

AmplifiDx develops the DX 100™ platform, a molecular point-of-care diagnostic device that utilizes advanced multiplex technology to deliver rapid and accurate test results for family and women's health. This device addresses the need for affordable and efficient diagnostics, enabling healthcare professionals and patients to obtain reliable results in under one minute with minimal hands-on time.

Amplo Biotechnology develops AAV-based gene therapies targeting the neuromuscular junction to treat genetic disorders such as Congenital Myasthenic Syndromes. Their lead candidates, AMP-101 and AMP-201, deliver the Dok-7 and Collagen Q proteins, respectively, to restore critical muscle function and address the underlying causes of these debilitating conditions.

Anvil Diagnostics develops smart reagents and algorithms to enhance digital PCR for detecting invasive infections. The company uses machine learning to design DNA sensors that identify pathogen gene signatures from complex samples. This approach enables fast, comprehensive pathogen quantification suitable for routine use in hospital settings.

Aquacycl utilizes BioElectrochemical Treatment Technology (BETT) to efficiently treat high-strength industrial wastewater while ensuring regulatory compliance and reducing greenhouse gas emissions by up to 90%. Their system offers significant cost savings by eliminating hauling fees and lowering energy consumption, enabling businesses to focus on their core operations.

Basilard BioTech develops Celletto™, a novel nanomechanical gene delivery platform for Cell and Gene Therapy (CGT) engineering. This mechanoporation solution delivers genes to the cell nucleus efficiently without compromising viability. Celletto™ addresses manufacturing bottlenecks by offering a more scalable and cost-effective alternative to traditional viral and non-viral gene delivery methods.

BRIUS develops the Brava System, a custom-fit orthodontic solution that utilizes Independent Tooth Movement technology to achieve invisible teeth straightening without the need for wires or removable devices. This approach significantly reduces treatment time to 6-12 months and minimizes the number of required office visits to just 4-6, enhancing patient convenience and compliance.

The startup develops an artificial intelligence-based analytics platform that detects faults and anomalies in power line assets by analyzing visual data captured from helicopters, drones, and field personnel. This automation enhances inspection efficiency, reduces operational costs, and ensures compliance with safety regulations for utility companies managing critical infrastructure.

Chronus Health offers a portable diagnostic platform that utilizes proprietary electrical sensing, microfluidics, and machine learning to perform multi-analyte blood tests with results available in 15 minutes. This technology eliminates the need for sample preparation and trained technicians, making point-of-care testing more accessible and cost-effective for various clinical environments.

The startup operates a cloud-based platform that facilitates the management of pharmaceutical clinical trials through integrated planning, outsourcing, and financial contract management. By providing detailed insights and analytics on clinical portfolios and provider performance, the platform enhances operational efficiency and decision-making for businesses in the pharmaceutical sector.

The startup develops surgical devices specifically designed for soft tissue surgery and hernia repair, utilizing techniques that optimize tissue tension and reinforcement. Their technology reduces tissue stress at the surgical site, minimizing the risk of surgical failure and enhancing patient outcomes.

Delpor develops long-acting injectable therapies for chronic central nervous system disorders, using its proprietary PROZOR and NANOPOR delivery platforms to enable once-yearly dosing. The approach aims to improve patient adherence in conditions such as schizophrenia and opioid use disorder.

Duo Oncology develops tumor-responsive nanomedicines using DNA self-assembly principles to create ultrasmall particles. These particles deliver a duo of anti-cancer therapies directly within the tumor microenvironment where they are released by environmental triggers. This platform is designed to improve outcomes for difficult-to-target and stroma-rich tumors.

The startup develops a network of underground tunnels for the transportation of clean renewable energy, broadband connectivity, and essential services like clean water and efficient parcel movement. This infrastructure addresses the lack of access to reliable energy and communication services in underserved communities, promoting sustainable development and connectivity.

EverestLabs.AI develops an AI-driven robotics platform that automates the sorting of recyclables in materials recovery facilities, enhancing operational efficiency and recovery rates. By capturing and analyzing object-level data, the technology reduces labor costs and increases the recovery of valuable materials, such as aluminum cans, from the waste stream.

Eversun provides portable, battery‑powered LED light towers that deliver up to 100,000 lumens of daylight‑balanced illumination without fuel, noise, or emissions. Their solar‑charged nano‑grid platform can be set up by a single operator in under 60 seconds and supports interchangeable power, sensor, and connectivity payloads for construction sites, events, defense, and other off‑grid applications.

GroGuru provides a Continuous Root Zone Monitoring solution that utilizes a patented Wireless Underground System to deliver real-time soil data and AI-driven irrigation recommendations. This technology enables farmers to optimize water usage and increase crop yields while addressing the critical challenge of water scarcity in agriculture.

HDAX is developing small molecules that utilize a novel two-site binding mechanism to target HDAC6, a key protein involved in microtubule stability and inflammatory processes. This approach addresses the limitations of conventional drug design by enhancing efficacy and safety for treating neuropathies and cardiovascular diseases.

The startup develops minimally invasive medical devices specifically designed for the treatment of vascular thromboembolism, focusing on peripheral and coronary artery diseases. Their interventional treatment systems aim to enhance patient outcomes by providing effective solutions for managing vascular conditions.

Inspirit offers a gamified virtual reality platform that enables educators to create custom science simulations and experiments using no-code tools, enhancing student engagement and critical thinking. The platform addresses the challenge of traditional teaching methods by providing immersive, hands-on learning experiences that improve knowledge retention and practical skills in STEM subjects.

Interface Bio develops next-generation, multi-targeted immunotherapies by integrating human biology and Artificial Intelligence. The company leverages a platform that mines natural product chemical scaffolds from commensal microbes for therapeutic development. This approach aims to generate safe and effective drug candidates for complex diseases like cancer and autoimmune disorders at an accelerated rate.

The startup offers a cloud-based boat monitoring platform that utilizes IoT devices to analyze maritime sensor data in real time. This technology enables operators to track critical performance metrics, minimizing the risk of unexpected breakdowns and reducing maintenance costs.